Retrospective Study of Aging and Sex-Specific Risk Factors of COVID-19 with Hypertension in China.

IF 3.4 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Cardiovascular Therapeutics Pub Date : 2022-06-28 eCollection Date: 2022-01-01 DOI:10.1155/2022/5978314
Juan Wang, Yili Zhang, Kexin Li, KangJia Du, Xinyi Huang, Zifeng Zhou, Yan Ma, Shuzhen Guo, Yong Hou, Quntang Li, Hongming Xu, Jin Huang, Qiuhua Huang, Hui Na, Jingwei Wang, Xiaoyan Wang, Yanhua Xiao, Junteng Zhu, Hong Chen, Zhang Liu, Mingxuan Wang, Linsong Zhang, Wei Wang, Haitong Wan
{"title":"Retrospective Study of Aging and Sex-Specific Risk Factors of COVID-19 with Hypertension in China.","authors":"Juan Wang,&nbsp;Yili Zhang,&nbsp;Kexin Li,&nbsp;KangJia Du,&nbsp;Xinyi Huang,&nbsp;Zifeng Zhou,&nbsp;Yan Ma,&nbsp;Shuzhen Guo,&nbsp;Yong Hou,&nbsp;Quntang Li,&nbsp;Hongming Xu,&nbsp;Jin Huang,&nbsp;Qiuhua Huang,&nbsp;Hui Na,&nbsp;Jingwei Wang,&nbsp;Xiaoyan Wang,&nbsp;Yanhua Xiao,&nbsp;Junteng Zhu,&nbsp;Hong Chen,&nbsp;Zhang Liu,&nbsp;Mingxuan Wang,&nbsp;Linsong Zhang,&nbsp;Wei Wang,&nbsp;Haitong Wan","doi":"10.1155/2022/5978314","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Coronavirus disease 2019 (COVID-19) has been a global threat that pushes healthcare to its limits. Hypertension is one of the most common risk factors for cardiovascular complications in COVID-19 and is strongly associated with disease severity and mortality. To date, clinical mechanisms by which hypertension leads to increased risk in COVID-19 are still unclear. Furthermore, additional factors might increase these risks, such as the consideration of age and sex, which are of interest when in search of personalized treatments for hypertensive COVID-19 patients.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of 543 COVID-19 patients in seven provinces of China to examine the epidemiological and clinical characteristics of COVID-19 in this population and to determine risk factors of hypertensive COVID-19 patients. We also used univariable and multivariable logistic regression methods to explore the risk factors associated with hypertensive COVID-19 patients in different age and sex subgroups.</p><p><strong>Results: </strong>Among the enrolled COVID-19 patients, the median age was 47 years (interquartile range (IQR) 34.0-57.0), and 99 patients (18.23%) were over 60 years old. With regard to comorbidities, 91 patients (16.75%) were diagnosed with hypertension, followed by diabetes, coronary disease, and cerebrovascular disease. Of the hypertensive COVID-19 patients, 51 (56.04%) were male. Multivariable analysis showed that old age, comorbid diabetes or coronary heart disease on admission, increased D-dimer, increased glucose, and decreased lymphocyte count were independent risk factors associated with hypertensive COVID-19 patients. Elevated total bilirubin (odds ratio [OR]: 1.014, 95% confidence interval [CI]: 0.23-1.05; <i>p</i> = 0.043) and triglycerides (OR: 1.173, 95% CI: 0.049-1.617; <i>p</i> = 0.007) were found to be associated with elderly hypertensive COVID-19 patients. In addition, we found that decreased lymphocytes, basophil, high-density lipoprotein, and increased fibrinogen and creatinine were related to a higher risk of disease severity in male patients. The most common abnormal clinical findings pertaining to female hypertensive COVID-19 patients were hemoglobin, total bile acid, total protein, and low-density lipoprotein.</p><p><strong>Conclusions: </strong>Factors associated with increased risk of hypertensive COVID-19 patients were identified. Results to the different age and sex subgroups in our study will allow for better possible personalized care and also provide new insights into specific risk stratification, disease management, and treatment strategies for COVID-19 patients with hypertension in the future.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2022-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240958/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2022/5978314","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 2

Abstract

Background: Coronavirus disease 2019 (COVID-19) has been a global threat that pushes healthcare to its limits. Hypertension is one of the most common risk factors for cardiovascular complications in COVID-19 and is strongly associated with disease severity and mortality. To date, clinical mechanisms by which hypertension leads to increased risk in COVID-19 are still unclear. Furthermore, additional factors might increase these risks, such as the consideration of age and sex, which are of interest when in search of personalized treatments for hypertensive COVID-19 patients.

Methods: We conducted a retrospective cohort study of 543 COVID-19 patients in seven provinces of China to examine the epidemiological and clinical characteristics of COVID-19 in this population and to determine risk factors of hypertensive COVID-19 patients. We also used univariable and multivariable logistic regression methods to explore the risk factors associated with hypertensive COVID-19 patients in different age and sex subgroups.

Results: Among the enrolled COVID-19 patients, the median age was 47 years (interquartile range (IQR) 34.0-57.0), and 99 patients (18.23%) were over 60 years old. With regard to comorbidities, 91 patients (16.75%) were diagnosed with hypertension, followed by diabetes, coronary disease, and cerebrovascular disease. Of the hypertensive COVID-19 patients, 51 (56.04%) were male. Multivariable analysis showed that old age, comorbid diabetes or coronary heart disease on admission, increased D-dimer, increased glucose, and decreased lymphocyte count were independent risk factors associated with hypertensive COVID-19 patients. Elevated total bilirubin (odds ratio [OR]: 1.014, 95% confidence interval [CI]: 0.23-1.05; p = 0.043) and triglycerides (OR: 1.173, 95% CI: 0.049-1.617; p = 0.007) were found to be associated with elderly hypertensive COVID-19 patients. In addition, we found that decreased lymphocytes, basophil, high-density lipoprotein, and increased fibrinogen and creatinine were related to a higher risk of disease severity in male patients. The most common abnormal clinical findings pertaining to female hypertensive COVID-19 patients were hemoglobin, total bile acid, total protein, and low-density lipoprotein.

Conclusions: Factors associated with increased risk of hypertensive COVID-19 patients were identified. Results to the different age and sex subgroups in our study will allow for better possible personalized care and also provide new insights into specific risk stratification, disease management, and treatment strategies for COVID-19 patients with hypertension in the future.

中国COVID-19合并高血压的年龄和性别特异性危险因素回顾性研究
背景:2019年冠状病毒病(COVID-19)已成为将医疗保健推向极限的全球威胁。高血压是COVID-19心血管并发症最常见的危险因素之一,与疾病严重程度和死亡率密切相关。迄今为止,高血压导致COVID-19风险增加的临床机制仍不清楚。此外,其他因素可能会增加这些风险,例如考虑年龄和性别,这是在寻找针对高血压COVID-19患者的个性化治疗时感兴趣的因素。方法:对中国7个省543例COVID-19患者进行回顾性队列研究,探讨该人群中COVID-19的流行病学和临床特征,并确定高血压COVID-19患者的危险因素。我们还采用单变量和多变量logistic回归方法探讨不同年龄和性别亚组高血压COVID-19患者的相关危险因素。结果:纳入的COVID-19患者中位年龄为47岁(四分位数间距(IQR) 34.0 ~ 57.0), 60岁以上患者99例(18.23%)。在合并症方面,91例(16.75%)患者被诊断为高血压,其次是糖尿病、冠心病和脑血管病。其中,男性51例(56.04%)。多变量分析显示,老年、入院时合并糖尿病或冠心病、d -二聚体升高、血糖升高、淋巴细胞计数下降是高血压COVID-19患者的独立危险因素。总胆红素升高(优势比[OR]: 1.014, 95%可信区间[CI]: 0.23-1.05;p = 0.043)和甘油三酯(OR: 1.173, 95% CI: 0.049-1.617;p = 0.007)与老年高血压患者相关。此外,我们发现淋巴细胞、嗜碱性粒细胞、高密度脂蛋白减少,纤维蛋白原和肌酐升高与男性患者疾病严重程度的高风险相关。女性高血压患者最常见的临床异常表现为血红蛋白、总胆汁酸、总蛋白和低密度脂蛋白。结论:确定了与高血压COVID-19患者风险增加相关的因素。在我们的研究中,不同年龄和性别亚组的结果将允许更好的个性化护理,也为未来COVID-19高血压患者的特定风险分层、疾病管理和治疗策略提供新的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cardiovascular Therapeutics
Cardiovascular Therapeutics 医学-心血管系统
CiteScore
5.60
自引率
0.00%
发文量
55
审稿时长
6 months
期刊介绍: Cardiovascular Therapeutics (formerly Cardiovascular Drug Reviews) is a peer-reviewed, Open Access journal that publishes original research and review articles focusing on cardiovascular and clinical pharmacology, as well as clinical trials of new cardiovascular therapies. Articles on translational research, pharmacogenomics and personalized medicine, device, gene and cell therapies, and pharmacoepidemiology are also encouraged. Subject areas include (but are by no means limited to): Acute coronary syndrome Arrhythmias Atherosclerosis Basic cardiac electrophysiology Cardiac catheterization Cardiac remodeling Coagulation and thrombosis Diabetic cardiovascular disease Heart failure (systolic HF, HFrEF, diastolic HF, HFpEF) Hyperlipidemia Hypertension Ischemic heart disease Vascular biology Ventricular assist devices Molecular cardio-biology Myocardial regeneration Lipoprotein metabolism Radial artery access Percutaneous coronary intervention Transcatheter aortic and mitral valve replacement.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信